IMA
Price
$4.04
Change
-$0.04 (-0.98%)
Updated
Oct 22 closing price
Capitalization
45.92M
20 days until earnings call
Intraday BUY SELL Signals
MNOV
Price
$1.41
Change
-$0.00 (-0.00%)
Updated
Oct 22 closing price
Capitalization
69.4M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMA vs MNOV

IMA vs MNOV Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMA vs. MNOV commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMA is a Hold and MNOV is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMA with price predictions
Oct 22, 2026

IMA's Indicator enters downward trend

The Aroon Indicator for IMA entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 293 similar instances where the Aroon Indicator formed such a pattern. In 259 of the 293 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMA as a result. In 93 of 110 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for IMA turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMA's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMA advanced for three days, in 172 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

IMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.323) is normal, around the industry mean (2.973). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (35.971) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. IMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MNOV with price predictions
Oct 22, 2026

MNOV in downward trend: price dove below 50-day moving average on October 06, 2026

MNOV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 45 of 53 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MNOV as a result. In 81 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for MNOV turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 39 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

The 10-day moving average for MNOV crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for MNOV entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Oscillator exited the oversold zone, 30 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.862) is normal, around the industry mean (2.973). P/E Ratio (-6.714) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MNOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
MNOV: Fundamental Ratings
MNOV
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
47
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMAMNOV
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 18 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
77%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (IMA: $4.09 vs. MNOV: $1.41)
Brand notoriety: IMA and MNOV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMA: 51% vs. MNOV: 7%
Market capitalization -- IMA: $45.92M vs. MNOV: $69.4M
IMA [@Biotechnology] is valued at $45.92M. MNOV’s [@Biotechnology] market capitalization is $69.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMA’s FA Score shows that 1 FA rating(s) are green while MNOV’s FA Score has 1 green FA rating(s).

  • IMA’s FA Score: 1 green, 4 red.
  • MNOV’s FA Score: 1 green, 4 red.
According to our system of comparison, MNOV is a better buy in the long-term than IMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMA’s TA Score shows that 4 TA indicator(s) are bullish while MNOV’s TA Score has 2 bullish TA indicator(s).

  • IMA’s TA Score: 4 bullish, 4 bearish.
  • MNOV’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, IMA is a better buy in the short-term than MNOV.

Price Growth

IMA (@Biotechnology) experienced а -3.66% price change this week, while MNOV (@Biotechnology) price change was -2.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

IMA is expected to report earnings on Nov 11, 2026.

MNOV is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMA
Daily Signal:
Gain/Loss:
MNOV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

IMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMA has been closely correlated with CELC. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if IMA jumps, then CELC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMA
1D Price
Change %
IMA100%
-0.98%
CELC - IMA
77%
Closely correlated
+6.51%
SLXN - IMA
62%
Loosely correlated
+0.12%
SYRE - IMA
36%
Loosely correlated
-0.67%
RVMD - IMA
32%
Poorly correlated
-3.39%
RAPP - IMA
31%
Poorly correlated
+5.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MHIP21.31N/A
N/A
Milliman Healthcare Inflation Plus ETF (MHIP)
BUYB43.36N/A
N/A
ProShares S&P 500 Buyback Aristocrats ETF (BUYB)
EQTY29.62-0.05
-0.17%
Kovitz Core Equity ETF (EQTY)
RIV9.90-0.08
-0.80%
RiverNorth Opportunities Fund
VBNB28.34-0.68
-2.35%
VanEck BNB ETF Common Shares Of Beneficial Interest (VBNB)